Spectral Molecular nets NIH grant
Cascade Technologies, a wholly owned subsidiary of Spectral Molecular Imaging, has received National Institutes of Health (NIH) research funding through collaboration with Omega Optical to accelerate the development of medical endoscopes enhanced with multispectral imaging technology.
The principal investigators are Gary E. Carver, PhD, director of research at Omega Optical of Brattleboro, Vt., and Daniel L. Farkas, PhD, chairman and CEO of Spectral in Beverly Hills, Calif.
Spectral said that the $750,000 Phase 2 award grant was awarded by the National Cancer Institute within the NIH, under the federal government's small business innovation research initiative upon successful completion of a $100,000 Phase 1 feasibility study earlier this year.
The new Omega/Spectral development program, scheduled for two years, focuses on completion of a prototype fast multispectral endoscope and its preclinical testing is scheduled at the Cedars-Sinai Medical Center in Los Angeles, added the company.
The principal investigators are Gary E. Carver, PhD, director of research at Omega Optical of Brattleboro, Vt., and Daniel L. Farkas, PhD, chairman and CEO of Spectral in Beverly Hills, Calif.
Spectral said that the $750,000 Phase 2 award grant was awarded by the National Cancer Institute within the NIH, under the federal government's small business innovation research initiative upon successful completion of a $100,000 Phase 1 feasibility study earlier this year.
The new Omega/Spectral development program, scheduled for two years, focuses on completion of a prototype fast multispectral endoscope and its preclinical testing is scheduled at the Cedars-Sinai Medical Center in Los Angeles, added the company.